Laboratorios Rubió, a Spanish pharmaceutical company that manufactures and markets Dolquine, a hydroxychloroquine-based medicine that is being used in the treatment of COVID-19, has announced that it has the capacity to triple its production to respond to the needs of the coronavirus.
The laboratory has reported in a statement that it has been made available to the Spanish Agency for Medicines and Health Products (Aemps) to be able to supply the drug based on its current production capacities.
Source: La Vanguardia
Hydroxychloroquine is a drug used for malaria prevention that has demonstrated an excellent antiviral effect in vitro against SARS-CoV infection. Various scientific publications have recently reported that chloroquine phosphate is showing marked efficacy and an acceptable safety level in treating pneumonia associated with COVID-19. In fact, following the published results of a multicenter study conducted on more than 100 patients, China’s regulatory authorities recommended the inclusion of the drug in the guidelines for diagnosing and treating pneumonia caused by COVID-19, as published by the National Health Commission of the People’s Republic of China.
Since then, various multicenter clinical trials have been launched to assess the efficacy and safety of both chloroquine and hydroxychloroquine in treating pneumonia associated with COVID-19.
Dolquine®’s active ingredient is hydroxychloroquine sulfate. This medicine is manufactured and marketed in Spain by Laboratorios Rubió since 2001. It is an antimalarial agent typically used in treating chronic patients with autoimmune diseases such as lupus erythematosus or rheumatoid arthritis, where its safety profile is widely established.
Laboratorios Rubió is a pharmaceutical company with global activity, committed to healthcare and strongly oriented towards both professionals and patients. For over 50 years, the company has introduced significant medicines and high value-added health products to the market that have led to a substantial improvement in people’s survival and quality of life.